BioStem Technologies, Inc.
corporate_fare Company Profile
BioStem Technologies, Inc. (NASDAQ:BSEM) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 16 items for BSEM at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 9/10. Across its 16 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for BSEM spans 10-Q, 8-K, 424B3, S-1.
Recent high-impact activity:
- BioStem 10-Q: Going Concern, $1.0M Cash, Unpaid $10M BioTissue Bill, DOJ Probe
- BioStem Q3 Loss Widens to $11.4M; Cash Falls to $1.0M as Guidance Is Raised
- Q3 Revenue Slips to $7.6M, Net Loss Widens to $11.4M as Cash Falls to $1.0M
- BioStem Raises $3M in Private Placement While $10M BioTissue Payment Remains Unpaid
- BioStem Registers 12.05M Shares for $40M Roth Equity Facility — Up to 40% Dilution
Short Interest & Short Volume
1.53 days to coverFINRA reported short interest of 286,950 shares in BSEM as of the October 30, 2026 settlement, a 14.0% decrease from the prior period — about 1.5 days to cover at its recent average daily volume. On November 20, 2026, 36.3% of BSEM volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for BSEM, detected from its recent SEC filings · based on capital-structure filings through 2026-09-29.
$40M Equity Facility Activated · Up to 40.2% Dilution
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →